Cash boost for SpectRx' cervical cancer detector:
This article was originally published in Clinica
Executive Summary
SpectRx is to accelerate its programme to develop a non-invasive cervical cancer detection device, after receiving a $1.4m grant award from the US National Cancer Institute. The grant will be primarily used to help fund the pivotal clinical trials necessary for approval to market the biophotonic device in the US. The Norcross, Georgia firm said that the trials would start within 90 days.